Assessing pentafecta achievement after robot-assisted radical cystectomy and its association with surgical experience: Results from a high-volume institution.

Journal: Urologic oncology
Published Date: Jan 29, 2022

Abstract

OBJECTIVES: Radical cystectomy (RC) represents the gold standard treatment for high-risk bladder cancer. Despite evidence suggesting that surgical experience correlates with perioperative and oncologic outcomes of robot-assisted RC (RARC), validated tools to assess its quality objectively are lacking. We aimed to evaluate the impact of RC-Pentafecta (absence of early major complications, absence of urinary diversion related sequelae at ≤12 months, absence of soft tissue surgical margins, ≥16 lymph nodes at final pathology and absence of clinical recurrence at ≤12 months) on oncological outcomes and the role of surgical experience on its achievement.

Authors

  • Pietro Piazza
    Division of Urology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
  • Carlo Andrea Bravi
    Department of Urology, Onze-Lieve-Vrouwziekenhuis, Aalst, Belgium; ORSI Academy, Melle, Belgium; Department of Urology and Division of Experimental Oncology, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy.
  • Stefano Puliatti
    Urology Department, University of Modena and Reggio Emilia, Modena, Italy.
  • Giovanni Enrico Cacciamani
    Catherine and Joseph Aresty Department of Urology, USC Institute of Urology, Keck School of Medicine/Norris Cancer Center, University of Southern California, Los Angeles, CA, USA.
  • Sophie Knipper
    Martini-Klinik Prostate Cancer Center, Hamburg, Germany.
  • Marco Amato
    Department of Urology, Onze-Lieve-Vrouwziekenhuis, Aalst, Belgium; ORSI Academy, Melle, Belgium; Department of Urology, University of Modena and Reggio Emilia, Modena, Italy.
  • Paolo Dell'Oglio
    Division of Oncology/Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy; Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, Canada.
  • Elio Mazzone
    Department of Urology, Onze Lieve Vrouw Hospital, Aalst, Belgium; ORSI Academy, Melle, Belgium.
  • Giuseppe Rosiello
    Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, Quebec, Canada.
  • Rui Farinha
    Department of Urology, Onze-Lieve-Vrouwziekenhuis, Aalst, Belgium; ORSI Academy, Melle, Belgium.
  • Luca Sarchi
    Department of Urology, Ospedale Policlinico e Nuovo Ospedale Civile S. Agostino Estense Modena, University of Modena and Reggio Emilia, Modena, Italy. Electronic address: 279948@studenti.unimore.it.
  • Simone Scarcella
    Department of Urology, Polytechnic University of Marche Region, Umberto I Hospital "Ospedali Riuniti", 71 Conca Street, 60126, Ancona, Italy. simoscarc@gmail.com.
  • Pawel Wisz
    Department of Urology, Onze Lieve Vrouw Hospital, Aalst, Belgium; ORSI Academy, Melle, Belgium.
  • Riccardo Schiavina
    1 Department of Urology, University of Bologna , Bologna, Italy .
  • Dries Develtere
    Department of Urology, Onze-Lieve-Vrouwziekenhuis, Aalst, Belgium; ORSI Academy, Melle, Belgium.
  • Pieter De Backer
    ORSI Academy Melle Belgium.
  • Ruben De Groote
    ORSI Academy Melle Belgium.
  • Frederiek D'Hondt
    General Surgery and Urology. OLV Hospital. Belgium.
  • Alexandre Mottrie
    ORSI Academy Melle Belgium.

Keywords

External Resources

Popular Topics
Recent Journals